CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised over $230M in Series B financing. The ...
Tessera’s reported revenue of $53.2 million was down 26.8% sequentially and 6.2% year over year. Tessera expects the Intellectual Property business to gradually become a smaller part of its revenue, ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. For several years, a rivalry has been ...
SOMERVILLE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S.
Tessera Therapeutics is planning to lay off 90 employees, the Flagship-founded biotech has warned. In a state layoff notice posted Wednesday, Tessera explained that the workforce reduction will affect ...
Latest Financing Round Will Support Tessera’s Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development “We are thankful for the support from our ...
Elon Musk’s SpaceX is weighing an initial public offering (IPO) at a valuation of over $1.5 trillion. Microsoft-backed OpenAI is also rumored to be seeking a trillion-dollar public debut. Given that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results